XML 70 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Note 12 - Related Party Transactions (Details Textual)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 13 Months Ended
Oct. 01, 2017
CAD ($)
Sep. 30, 2022
CAD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2017
USD ($)
Jan. 31, 2018
CAD ($)
Mar. 31, 2020
a
Dec. 31, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 14, 2017
Dec. 02, 2017
Jul. 12, 2017
Area of Land (Acre) | a                 10.4          
Operating Lease, Right-of-Use Asset     $ 195,703   $ 195,703         $ 229,284        
Operating Lease, Liability, Total     197,184   197,184                  
Lease Arrangement, 20 North Rear Road [Member]                            
Operating Lease, Monthly Rent               $ 4,000            
Lessee, Operating Lease, Term of Contract (Year)               5 years            
Operating Lease, Right-of-Use Asset     49,963   49,963           $ 68,547      
Operating Lease, Liability, Total     $ 47,028   $ 47,028           $ 65,467      
Lessee, Operating Lease, Discount Rate     8.00%   8.00%         8.00%        
Operating Lease, Expense     $ 8,690 $ 9,106 $ 17,409 $ 15,092                
Leases Office Space from R&D Labs Canada, Inc [Member]                            
Operating Lease, Monthly Rent $ 2,608 $ 3,390                        
Operating Lease, Right-of-Use Asset     145,740   145,740         $ 160,737        
Operating Lease, Liability, Total     $ 150,156   $ 150,156         $ 163,157        
Lessee, Operating Lease, Discount Rate     8.00%   8.00%         8.00%        
Operating Lease, Expense     $ 6,928 7,060 $ 13,253 12,039                
Former CEO [Member]                            
Ownership Percentage     5.00%   5.00%                  
Long-term Convertible Notes Payable to Multiple Private Investors [Member]                            
Debt Instrument, Interest Rate, Stated Percentage                           5.00%
CEN Biotech Ukraine [Member] | XN Pharma [Member]                            
Ownership Percentage     49.00%   49.00%             49.00%    
CEN Biotech Ukraine [Member]                            
Percentage of Related Party's Equity Interest Owned by Director                       25.50%    
Business Acquisition, Percentage of Voting Interests Acquired                       51.00%    
CEN Biotech Ukraine [Member]                            
Due from Related Parties, Total     $ 1,065,328   $ 1,065,328         $ 1,065,328        
Percentage of Related Party's Equity Interest Owned by Director                         51.00%  
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]                            
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings             $ 255,141              
Notes Receivable, Related Parties             44,859              
Joseph Byrne [Member]                            
Related Party Transaction, Due from (to) Related Party, Current, Total     (8,347)   (8,347)                  
Board Members and Officers [Member] | Consulting Fees [Member]                            
Related Party Transaction, Amounts of Transaction     31,200 $ 33,800 62,400 $ 65,000                
Due to Related Parties, Total     $ 267,800   $ 267,800         $ 263,900        
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]                            
Notes Payable, Related Parties             $ 300,000